Share on

Global Non-Invasive Prenatal Testing Market Size, Share, Trends, COVID-19 Impact & Growth Analysis Report – Segmented By Instruments, Method, Application & Region - Industry Forecast (2022 to 2027)

Published: January, 2022
ID: 2700
Pages: 176
Formats: report pdf report excel report power bi report ppt

Global Non-Invasive Prenatal Testing Market Size (2022 to 2027)

The size of the global non-invasive prenatal testing market is estimated to be growing at a CAGR of 15.6% during the forecast period. The market size is predicted to be USD 4.65 billion by 2027 from USD 2.25 billion in 2022.

Various industries of various regions manage this Non-Invasive Prenatal Testing (NIPTherefore, The study of NIPT is a combination of qualitative and quantitative, highlighting the market developments, challenges, opportunities, and analyses available and trends in NIPT.


Growth in reimbursements for the NIPT sector and maternal age growth, the development of acquiring technologies, and non-invasive parental testing products are a few of the significant factors driving the global non-invasive prenatal testing market growth.

Serving regulatory procedures, which take more time to approve new products, and the rapid development of a new device method are the factors that restrict the market growth. Lack of having expert professionals and strict regular guidelines that slows down the process of approvals and marketing are other attributes degrading the demand of the Global Non-Invasive Prenatal Testing Market.

Advance genome sequencing technology turnaround time and the complexity of diagnosis with the next-generation sequencing create growth opportunities for the Non-Invasive Prenatal Testing Market. NGS technology provides many opportunities to develop non-invasive diagnostic procedures for the early and correct detection of various genetic disorders.


Meticulous primary and secondary research techniques and data analysis, including qualitative and quantitative research of analysts, directly impede the demand of the non-invasive prenatal testing market. Positive results would require a test with the help of invasive methods such as CVS and amniocentesis, which pose a significant challenge for the Global NIPT market.

Impact of COVID-19 on Non-Invasive Prenatal Testing Market:

Non-invasive prenatal testing (NIPT) services have been halted to avoid the spread of the COVID-19 virus; the outbreak is expected to affect the non-invasive prenatal testing market. Non-invasive prenatal testing (NIPT), also known as cell-free DNA testing, is a useful addition to the variety of screening tests available to detect fetal chromosomal abnormalities. One of the reasons preventing hospitals and diagnostic centers from offering non-invasive prenatal screening (NIPS) services is the immense demand for hospitals to offer services to COVID-19 patients. On the other hand, COVID-19 lockdown has also brought NIPT to the mainstream. It provides high-accuracy screening with a low risk of infection than invasive procedures like amniocentesis and chorionic villus sampling (CVS). In addition, multiple research trials are being performed to assess the effect of COVID-19 on the market for non-invasive prenatal testing. During the COVID pandemic, in-vitro diagnostics manufacturers and clinical testing laboratories collaborate with research organizations to assess the impact of SARS-CoV-2 infection on pregnancy and congenital disabilities in newborns the need for non-invasive prenatal testing. As a result, the industry experienced a short-term sales decline in 2020, causing a change in business focus and a delay in product launches. Thus COVID-19 outbreak has had only a minor effect on the market for non-invasive prenatal testing (NIPT). 




Market Size Available

2021 to 2027

Base Year


Forecast Period

2022 to 2027

Segments Covered

By Instruments, Methods, Application, End-User, and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Covered

North America, Europe, Asia Pacific, Latin America, Middle East & Africa


This research report on the global non-invasive prenatal testing market has been segmented and sub-segmented based on the instruments, methods, application, end-user, and region.

Non-Invasive Prenatal Testing Market - By Instruments:

  • Ultrasound
  • NGS
  • PCR
  • Microarray

Based on the instruments, the ultrasound segment is expected to lead the market with the highest share during the forecast period due to the increased number of tests and products for NIPT and growing awareness among pregnant women.

Non-Invasive Prenatal Testing Market - By Method:

  • FCMB
  • Cf-DNA

Based on the method, the cf-DNA segment is accounted for the largest share market, and it is to advance technology; this is the most considerable market value. FCMB segment is projected to have rapid growth in the NIPT market.

Non-Invasive Prenatal Testing Market - By Application:

  • Trisomy
  • Microdeletion
  • Genetics
  • Rh factor

Based on the application, the Trisomy segment holds the most massive value of the overall NIPT market. Increasing occurrences of maternal age and the low cost of NIPT methods enhance the demand of the Global Non-Invasive Prenatal Testing Market.

Non-Invasive Prenatal Testing Market - By End-users:

  • Hospital
  • Diagnostic Labs

Based on end-users, the diagnostic labs account for the largest share of the NIPT market by using a well-supply of necessary items and expert technicians. Government agencies' significant investments to improve healthcare infrastructure also accelerate the demand of the Global Non-Invasive Prenatal Testing Market.

Non-Invasive Prenatal Testing Market - By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • The Middle East and Africa

Regionally, North America is forecasted to lead the Global Non-Invasive Prenatal Testing Market during the forecast period, with the U.S. accounting for a significant share. North America’s lead is driven by high-end technology; it is a developed market combined with the growing incidence of genetic abnormalities. U.S and Canada are the major countries contributing to the NIPT market. Among these, the United States is ruling the market in this region.

The European market is the second-largest regional market in the global non-invasive prenatal testing market share, owing to the rising awareness and establishment of MIPT procedures. The growing occurrence rate of miscarriages and difficulties, increasing acceptance among pregnant women as a secured alternative to amniocentesis, and awareness of prenatal genetic issues further accelerate the European NIPT market growth.

However, Asia-Pacific is estimated to grow at the highest CAGR during the forecast period, majorly because of exponentially greater population numbers.

The NIPT market for Latin America is projected to grow at a stable rate during the forecast period due to the Y-O-Y growth in the genetic disorders scattered among a vast population base. Increasing awareness about genetic abnormalities is escalated to drive the NIPT market.

The Middle East & Africa for non-invasive prenatal testing is projected to grow at a sluggish CAGR from 2020 to 2025. Launch of new and more advanced NIPT products and their availability and increasing importance for non-invasive techniques over invasive ones fuel this region's market.


Some of the most promising companies holding a significant share in the Global Non-Invasive Prenatal Testing Market profiled in this report are GE Healthcare (U.S.), Koninklijke Philips N.V. (Netherlands), Illumina, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Pacific Biosciences of California, Inc. (U.S.), PerkinElmer, Inc. (U.S.), QIAGEN N.V. (Germany), Agilent Technologies, Inc. (U.S.) and Beijing Genomics Institute (China).


  • On June 04, 2019, Illumina, Inc. introduced the new version of VeriSeq non-invasive prenatal testing solution2, a CE –IVD, next-generation sequencing-based approach that provides exact information regarding fetal chromosomal status early as 10weeks of gestation using a single maternal blood draw. 
  • On July 10, 2018, PerkinElmer announced that it is collaborating with Women & Infant’s Hospital of Rhode Island to estimate an innovative test method using the Vanadis NIPT system, which is under development currently not available in clinical use in the United States.
  • On June 08, 2017, LifeCodexx AG partnered with Life-Cell to introduce Non-Invasive prenatal testing in India, leading baby, and mother safety healthcare providers to bring PrenaTest qNIPTTM for the first time in India.  

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us:

Click for Request Sample